These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9491268)

  • 1. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF; Lensen RP; Bertina RM
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
    Ivey LM; Thom JY; Ivey JG; Baker RI
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
    Reuner KH; Litfin F; Patscheke H
    Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.
    Aboud MR; Ma DD
    Br J Haematol; 1997 Jun; 97(4):798-803. PubMed ID: 9217178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
    Castaman G; Tosetto A; Ruggeri M; Rodeghiero F
    Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
    Ts'ao C; Neofotistos D; Oropeza M; Vahabinejad S; Finn WG
    Am J Hematol; 1997 Mar; 54(3):214-8. PubMed ID: 9067500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
    van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
    Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
    Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
    Gessoni G; Valverde S; Valle L; Gessoni F; Caruso P; Valle R
    Int J Lab Hematol; 2017 Aug; 39(4):418-422. PubMed ID: 28318106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma.
    Kapiotis S; Quehenberger P; Jilma B; Handler S; Pabinger-Fasching I; Mannhalter C; Speiser W
    Am J Clin Pathol; 1996 Nov; 106(5):588-93. PubMed ID: 8929467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
    Baig MA
    Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
    Sartori MT; Simioni P; Patrassi GM; Theodoridis P; Tormene D; Girolami A
    Clin Appl Thromb Hemost; 2000 Jan; 6(1):36-40. PubMed ID: 10726047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not.
    Simioni P; Girolami A
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):825-7. PubMed ID: 7865690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation.
    Castoldi E; Govers-Riemslag JW; Pinotti M; Bindini D; Tans G; Berrettini M; Mazzucconi MG; Bernardi F; Rosing J
    Blood; 2003 Dec; 102(12):4014-20. PubMed ID: 12881304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.